General Information of Drug (ID: DM98NOU)

Drug Name
Batiraxcept
Synonyms AVB-S6-500
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 3 [1]
Cross-matching ID
TTD ID
DDRX30

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
AXL receptor tyrosine kinase ligand (GAS6) TT69QD2 GAS6_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04729608) A Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC). U.S.National Institutes of Health.
2 Target-Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model-Informed Dose Selection for the First-in-Human Study of AVB-S6-500. Clin Transl Sci. 2020 Jan;13(1):204-211.